正常な発達とがんにおけるeIF4E用量の差異的要件

Morgan L Truitt¹, Crystal S Conn¹, Zhen Shi²

¹Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

Cell

|June 23, 2015

まとめ

ユカリオット開始因子4E (eIF4E) の50%減少は,特定のmRNAsの翻訳を制限することによって,がん細胞の変容を阻害する. 癌細胞は過剰なeIF4Eを腫瘍発生のために乗っ取ります.

科学分野:

分子生物学は分子生物学である.
癌生物学癌生物学について
遺伝学遺伝学とは

背景:

ユカリオット初期化因子4E (eIF4E) は,主要なキャップ結合タンパク質である.
生物体トランスレーション用量におけるその役割は完全に理解されていません.
eIF4Eは,がんの発症に関与している.

研究の目的:

eIF4E用量に対する生物学的要件を調査する.
細胞変容と腫瘍発生におけるeIF4Eレベルの役割を理解する.

主な方法:

Eif4eハプロイン不十分なマウスモデルの生成.
ゲノム全体のトランスレーションプロファイリング.
腫瘍性変異中のmRNA翻訳の分析.

主要な成果:

eIF4E (ハプロイン欠乏症) の50%減少は,正常な発達や全タンパク質合成に影響を与えませんでした.
減少したeIF4Eは,細胞の変容を著しく阻害しました.
eIF4Eの投与量は,反応性酸素種調節に関与する特定の5' UTRsを持つmRNAを翻訳するのに重要である.
このトランスレーションプログラムは,がん細胞の生存を活かします.

結論:

eIF4Eのレベルは,正常な発達のために過剰です.
癌細胞は,eIF4Eの上昇を悪用して,腫瘍発生を支援する翻訳プログラムを実行します.
eIF4Eの投与量をターゲットにすることは,がんに対する潜在的な治療戦略です.

さらに関連する動画

13:54

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death

Published on: October 21, 2012

11.4K

10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.7K

関連する概念動画

02:38

Mitogens and the Cell Cycle

8.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

8.4K

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.8K

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

2.8K

02:53

Adaptive Mechanisms in Cancer Cells

7.4K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

7.4K

02:59

Biological Effects of Radiation

19.7K

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...